Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
Pfizer Inks Real-World Oncology Data Collaboration With Concerto HealthAI
AACR: BMS, clinging to Opdivo’s lung cancer share, highlights long-term data
AACR: BMS, clinging to Opdivo’s lung cancer share, highlights long-term data
Top 15 Best-Selling Drugs of 2018
Top 15 Best-Selling Drugs of 2018
Bristol-Myers Squibb Going All out to Sell Celgene Deal
Bristol-Myers Squibb Going All out to Sell Celgene Deal
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
Top 10 Immuno-Oncology Startups
Top 10 Immuno-Oncology Startups
J&J Earns Spot in Fortune’s Top 50 Most Respected Companies
J&J Earns Spot in Fortune’s Top 50 Most Respected Companies
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Marketing Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Marketing
Between Merck and Pfizer, the race is on in kidney cancer—but analysts are calling it early
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Upcoming events – Cancer readouts for Merck & Co and Seattle
Upcoming events – Cancer readouts for Merck & Co and Seattle
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
The Top 6 Companies of the Pharmaceutical Innovation Index 2018
The Top 6 Companies of the Pharmaceutical Innovation Index 2018
The skeptics were right: Bristol-Myers has pulled a crucial Opdivo lung filing as it awaits more data
The skeptics were right: Bristol-Myers has pulled a crucial Opdivo lung filing as it awaits more data
Look out for a Q4 surprise from BMS’ Opdivo, but Merck’s Keytruda will stay on top: analyst
Look out for a Q4 surprise from BMS’ Opdivo, but Merck’s Keytruda will stay on top: analyst
The Celgene Legacy: Innovative Science and Price Gouging
The Celgene Legacy: Innovative Science and Price Gouging
